The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVI.b

Imaging: Ground-glass opacities (GGO) / shadowing

Publications

Sherrod AM, Brufsky A, Puhalla S

A case of late-onset gemcitabine lung toxicity.

Clinical Medicine Insights. Oncology. 2011;5:171-6

Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, Schellens JH, Rodenhuis S

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.

Investigational new drugs. 2007;25(3):279-81

Rosado MF, Kett DH, Schein RM, Baraona FJ, Sridhar KS

Severe pulmonary toxicity in a patient treated with gemcitabine.

American journal of clinical oncology. 2002;25(1):31-3

Boiselle PM, Morrin MM, Huberman MS

Gemcitabine pulmonary toxicity: CT features.

Journal of computer assisted tomography. 2000;24(6):977-80